Chronically sprained ankle - three months after stem cell treatment by Dr Harry Adelson
Stacy discusses her results from her stem cell treatment by Dr Harry Adelson for her chronically sprained ankle http://www.docereclinincs.com.
By: Harry Adelson, N.D.
Read the original post:
Chronically sprained ankle - three months after stem cell treatment by Dr Harry Adelson - Video
(WMC-TV) - More than 60 percent of American households include at least one pet, and for many of us they are more like family than a four-legged friend.
Eight-year-old Sadie suffers from debilitating arthritis. To owners Greg and Marsha James, she is a miracle dog.
"She's my little girl, she's my baby," said owner Marsha. "I didn't know if we could do anything and what we could do, I thought we were gonna lose her."
Last year she could not even walk, but a scientific breakthrough using her own stem cells put the pep back in her step.
"Stem cell is used to treat chronic arthritic conditions," said Dr. Kathy Mitchener, DVM at Angel Care Center for Pets.
Dr. Kathy Mitchener removed a few ounces of fat from Sadie's tummy; a lab extracted the stem cells, which were then re-injected into her trouble spots.
"If there's joint destruction, if there's changes in metabolism then they change themselves and multiply to help address those issues," said Mitchener.
Stem cell treatment proves to be just one of many medical miracles at the Angel Care Cancer Center for Pets in Bartlett.
Take Rylee for example. The 2-year-old golden retriever has an unusual type of lymphoma.
"Riley was very young, and that's very , very frightening to have such a devastating disease," said Mitchener.
View original post here:
Stem cell treatment, other breakthroughs giving pets longer, healthier lives
Inhibition of a prostaglandin with nonsteroidal anti-inflammatory drugs has been found to cause stem cells to leave marrow, where they could be harvested for patients with blood disorders
Tino Soriano/National Geographic Society/Corbis
Aspirin-like drugs could improve the success of stem-cell transplants for patients with blood or bone-marrow disorders, a study suggests. The compounds coax stem cells from bone marrow into the bloodstream where they can be harvested for use in transplantation and they do so with fewer side effects than drugs now in use.
For patients with blood disorders such as leukemia, multiple myeloma or non-Hodgkins lymphoma, transplantation of haematopoietic stem cells precursor cells that reside in the bone marrow and give rise to all types of blood cell can be an effective treatment.
Previous work has shown that prostaglandin E2, or PGE2, a lipid known to regulate multiple bodily reactions including pain, fever and inflammation, also has a role in keeping stem cells in the bone marrow. In the latest study, researchers show that in mice, humans and baboons, inhibition of PGE2 with non-steroidal anti-inflammatory drugs (NSAIDs) causes stem cells to leave the bone marrow.
Releasing the stem cells The team gave baboons and humans an NSAID called meloxicam. They saw a subsequent increase in the numbers of haematopoietic stem cells in the bloodstream.
The researchers think that the departure of stem cells is caused by the disturbance of a group of bone-forming cells called osteoblasts. These cells secrete a protein called osteopontin that hooks the stem cells to the bone marrow. Inhibiting PGE2 would disrupt the production of osteopontin.
At present, doctors use a drug called filgrastim to mobilize haematopoietic stem cells in donors or in patients undergoing autotransplantation (in which they receive their own stem cells). In patients with multiple myeloma or non-Hodgkins lymphoma, however, and in some donors, stem cells dont mobilize well with filgrastim and other drugs in its class. Using NSAIDs such as meloxicam could enhance filgrastims efficacy, says lead author Louis Pelus of the Indiana University School of Medicine in Indianapolis. The study appears in Nature.
Meloxicam also has comparatively few side effects, says Pelus. He and his colleagues found that other NSAIDs, including aspirin and ibuprofen, can also mobilize haematopoietic stem cells, but these drugs can cause gastrointestinal upset in patients. PGE2 controls the secretion of hydrochloric acid in the stomach, and when you block that youve reduced your ability to control acid secretion. Meloxicam doesnt do that as badly as many of the other [drugs] do, he says.
For Charles Craddock, director of the blood and marrow transplant unit at the Queen Elizabeth Hospital in Birmingham, UK, the results might also hold clues about how to mediate the tricky process of getting cells back to the bone marrow once transplanted. If youre beginning to understand what mediates cells moving out, you might be able to understand what mediates cells moving in. If you can make bone marrow more sticky, when you put cells back, you might be able to keep them in.
Follow this link:
Painkillers Could Prove Helpful in Stem-Cell Transplants
A new study marks a step toward stem cell treatment of infertility
Clouds Hill Imaging Ltd./Corbis
The causes of infertility, which affects around 10% of couples, are often unknown, but may in some cases result from the body's inability to produce viable gametes also known as sperm and egg cells. The first study of the development of such 'germ cells' from humans could help scientists to learn how to create them in the laboratory instead.
Even though the reproductive age for humans is around 1545 years old, the precursor cells that go on to produce human eggs or sperm are formed much earlier, when the fertilized egg grows into a tiny ball of cells in the mothers womb. This ball of cells contains pluripotent stem cells blank slates that can be programed into any type of cell in the body and researchers are hoping to use these stem cells to treat various conditions, including infertility.
But little is known about the early developmental stages of human gametes owing to the sensitivity of working with human tissue and most work in this area has been conducted using mice. In a Nature Cell Biology paper today, researchers from the University of California, Los Angeles, trace the development of early germ cells in human fetuses of between 6 to 20 weeks and analyzed when genes were turned on or off.
The DNA within these early germ cells carries 'epigenetic modifications' structural changes that do not affect the DNA sequence itself but do affect the way that genes are expressed. These changes may have accumulated during the parents lives, and need to be erased during the fetal stage. The study found two major events that wipe out, or reprogram, epigenetic modifications. Most of this reprograming happened before 6 weeks, but the authors found a second event that completes the reprograming after 6 weeks.
This is an important and fundamental paper for understanding human germ-line cells and finding the basic information about human germ-cell biology, says reproductive biologist Evelyn Telfer of the University of Edinburgh, UK. The researchers are clearly working in an uncharted area.
The Los Angeles team worked with anonymized samples from aborted fetuses (after consent) from the University of Washington's Birth Defects Research Laboratory in Seattle.
The researchers also observed that 6-week-old germ cells created in the lab do not match a 6-week-old human germ cell, suggesting that there is a blockage in the development of lab cells that scientists are failing to understand.
Next, we need to look at what is missing to coax immature germ cells to become eggs or sperm in the lab. If we have no road map to follow, then we are just guessing. Now we have a snapshot of what these cells should look like, we can start to try and mimic them, says study co-author Amander Clark.
Follow this link:
First Road Map of Human Sex-Cell Development
The Sultan bin Abdulaziz Humanitarian City (SAHC) announced Tuesday its intention to take stem cell transplantation to new heights by using the method to cure spinal cord injuries. The announcement was made by Prince Khaled bin Sultan, chairman of the Sultan bin Abdulaziz Al-Saud Foundation (SAAF), during the international spinal cord injury conference 2014, which kicked off at the SAHC headquarters on Tuesday. The theme of the conference, which ends on Thursday, is Toward a Better Quality of Life. The conference, first introduced in Australia and New Zealand, is being held for the first time in the Middle East. The technology, in collaboration with the US-based University of Miami, will revolutionize the scope of paralysis surgery in the Kingdom, making it a leader in the field. An accord on collaboration between the SAHC and the Miami Project to Cure Paralysis (MPCP), the first center in the US to receive approval from the supervisory board of the Food and Drug Administration for stem cell therapy, was also signed. Prince Khaled said that the transfer of this technology comes amid efforts to help families cope with the life-changing effects of spinal cord injuries. Prince Khaled said many people between the ages of 16 and 22 suffer such debilitating injuries. The MPCP works on several research and rehabilitation programs in the field of spinal cord and traumatic brain injury, he said. The transfer of this technology to the SAHC will make Saudi Arabia one of the first countries in the region to benefit from the revolutionary treatment of spinal cord injury through stem cell research. SAHC Executive President Abdullah Zarah said the conference would address the latest findings of modern science in the field of spinal cord injury and stem cell transplantation. Around 1,500 Saudis are afflicted with spinal cord injuries every year due to accidents. Rizman Hamid, a senior neurology lecturer at University College London, told Arab News that being afflicted with this type of injury is a lifelong condition. Such critical ailments require follow-up, with radiological investigation to optimize bladder function. Patients should undergo regular investigation as a means of detecting potential problems in the bladder, which can lead to kidney damage, he said. He added that another major problem resulting from spinal cord injuries, especially among women, is urinary incontinence, which has severe and adverse effects on patients. This condition can be cured through a procedure known as the transobtruator tape. This is a minimally invasive procedure that has good long-term results, he said. Firas Sirhan, director of the Center of Excellence for Telehealth and Assisted Living (CETAL) at Buckinghamshire New University in Middlesex, England, said that the use of technology and health care practice is becoming more visible in the treatment and management of spinal cord injuries. Telehealth represents an entirely new way of managing injury that does not easily fit within existing health care frameworks, he said. The use of the telehealth model has contributed to empowering patients to become more involved in the self-management of their condition. Telehealth could be an effective tool that contributes to allowing health care professionals, as well as patients, to recognize and identify any changes in medical conditions. He added that the center can assist in developing packages that combine tested clinical service models with assessed technology to present workable telehealth services based on specific needs.
See the original post here:
Stem cell technology to cure spinal cordv injuries introduced in KSA
stem cell therapy treatment for Cerebral Palsy with Mental Retardation by dr alok sharma, mumbai
improvement seen in just 5 daysafter stem cell therapy treatment for Cerebral Palsy with Mental Retardation by dr alok sharma, mumbai, india. Stem Cell Thera...
By: Neurogen Brain and Spine Institute
19. Mr. You with Cerebellar Atrophy Get Stem Cell Treatment (Before)
Mr. You, 45 years old, was diagnosed with cerebellar atrophy in 2007. In May 2009, he came to our stem cell center for first course stem cell treatment. Cond...
By: Cells Center China
Visit link:
19. Mr. You with Cerebellar Atrophy Get Stem Cell Treatment (Before) - Video
19. Mr. You with Cerebellar Atrophy Get Stem Cell Treatment (After)
Mr. You, 45 years old, was diagnosed with cerebellar atrophy in 2007. In May 2009, he came to our stem cell center for first course stem cell treatment. Cond...
By: Cells Center China
Link:
19. Mr. You with Cerebellar Atrophy Get Stem Cell Treatment (After) - Video
Orange County, CA (PRWEB) March 03, 2014
The top stem cell treatment clinic in Southern California, Telehealth, is now offering several knee pain treatment options for avoiding joint replacement. The regenerative medicine treatments involve either platelet rich plasma therapy, bone marrow derived stem cell injections or blood derived stem cell treatment. Call for more information and scheduling call (888) 828-4575. The treatments may be completely or partially covered by insurance.
Although knee replacement procedures have been exceptionally successful for reducing one's pain and improving functional abilities, there are some risks associated with the procedure, along with the fact they are not meant to last forever. Unlike conventional nonoperative treatments, such as steroid injections, regenerative medicine treatments maintain the ability to repair and regenerate arthritic tissue as opposed to simply masking pain.
The Board Certified doctors at Telehealth have extensive experience and regenerative medicine therapies for degenerative arthritis of the knee. Stem cell therapy for arthritis has been shown in several small published studies to provide excellent pain relief and maintain cartilage in the knee.
All of the treatments provided are low-risk and outpatient. They involve blood or bone marrow from the patient him or herself, which reduces the risk profile even more.
Telehealth Medical Group has two locations in Southern California. One is right in Santa Ana, while the other is in Upland. Appointments are readily available. Call for more information and scheduling to (888) 828-4575.
See original here:
Southern California Stem Cell Clinic, Telehealth, Now Offering Several Knee Treatment Options to Avoid Joint Replacement
Jesse Freeman, 71, suffered a major heart attack at home Had surgery to repair a blocked artery and to insert a stent to keep it open He was then asked to take part in a new study into the use of stem cells These are 'master cells' which can turn into almost any other type of cell in the body, replacing damaged cells He had bone marrow removed from his hip and infused into his heart It is hoped this will regenerate to help heal his damaged heart
By Emma Innes
PUBLISHED: 08:36 EST, 3 March 2014 | UPDATED: 08:52 EST, 3 March 2014
A British man has become the second patient in a Europe to have pioneering stem cell treatment in a bid to prolong his life.
Jesse Freeman, 71, was invited to take part in the landmark trial after suffering a major heart attack at home.
Surgeons repaired a blocked artery and inserted a stent to keep it open after he was rushed to hospital.
Jesse Freeman (pictured with his wife, Christine) has become the second person in Europe to have pioneering stem cell treatment after a heart attack. It is hoped the procedure will cause his damaged heart muscle to regenerate and that it could eventually become common practice in the treatment of heart attack patients
But while recovering in hospital, he was asked to take part in the major new study to see if heart attack patients can benefit from being treated with their own stem cells.
These are 'master cells' which can turn into almost any other type of cell in the body, replacing damaged cells.
Doctors at the London Chest Hospital, in Bethnal Green, removed bone marrow from Mr Freeman, a grandfather, without general anaesthetic and the cells were then infused into his heart.